Feds probe ISTA promotions

Share this article:
ISTA Pharmaceuticals issued a statement reporting a subpoena received from the US Attorney's Office in Buffalo, “requesting the production of documents regarding promotional, educational and other activities relating to Xibrom (bromfenac sodium ophthalmic solution) 0.09%.”  

Xibrom is an ophthalmic solution indicated for the treatment of inflammation and ocular pain following cateract surgery.  Representatives of ISTA Pharmaceuticals were not immediately available for comment.

ISTA Pharmaceuticals previously reported clinical trial data showing “no statistically significant difference” between Xibrom and a new product, Xibrom QD.  Xibrom QD, to be taken once-per-day, would potentially replace Xibrom, taken twice-per-day.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...